At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
UBX0101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee
In Brief
A Phase 2 clinical trial evaluating UBX0101 and Placebo for Osteoarthritis, Knee. Completed, enrolled 183 participants across 20 sites.
Detailed Summary
A study to assess efficacy, safety, and tolerability of a single-dose intra-articular administration of UBX0101 in patients with moderate to severe painful knee osteoarthritis (OA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartOct 2019
Primary CompletionMay 2020
Study CompletionAug 2020
TodayJul 2026
First PostedOct 17, 2019
Enrollment StartOct 30, 2019
Primary CompletionMay 20, 2020
Study CompletionAug 7, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.7 years ago
Interventions
UBX0101drug
Investigational drug intra-articular injection
Placeboother
Placebo intra-articular injection